Combining Dapagliflozin and Eplerenone Further Reduces Albuminuria in CKD
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Diabetic Nephropathy
Underuse of Diabetic Kidney Disease Therapies Reported
Study findings highlight an “unmet need” for newer therapies.
SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Medtronic’s SCS Therapy Approved for Painful Diabetic Peripheral Neuropathy
These SCS devices were cleared based on data from a randomized controlled trial published in the journal Diabetes Care in 2014.
Finerenone Provides CV, Renal Benefits in Diabetes Across CKD Spectrum
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Dapagliflozin Safe, Effective in Advanced Chronic Kidney Disease
Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.
ADA: Efpeglenatide Lowers Risk for Adverse CV Events in T2DM
Findings among patients with type 2 diabetes and history of cardiovascular disease or current kidney disease
Renoprotective Effect of SGLT2 Inhibitors Mediated Largely by Hematocrit
Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.
Study: Etelcalcetide Can Be Used Safely in Diabetic Nephropathy
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
Semaglutide Effective in High-Risk Diabetic Kidney Disease
More than two-thirds of patients experienced a more than 5% weight loss with 12 months of etelcalcetide treatment.
